Aesthetics Magazine是由Allergan Aesthetics建立的網上雜誌，致力為讀者提供醫學美容及護膚瘦身等熱門內容。透過多元化的生活資訊，讓你增進對醫美及基礎保養的認識，成為Better Me！Allergan Aesthetics是全球醫學美容領導者，旗下品牌BOTOX®、Juvéderm®及CoolSculpting® 均是其界別內的全球No.11-3，分別以去皺、提昇輪廓及冷凍溶脂滿足用家不同需要，讓你散發自信光彩，找回專屬自己的獨特美。
提昇輪廓9-11Juvéderm®長效透明質酸榮獲歐盟CE12及美國FDA13認證，總銷量高達1億支14。全線產品均採用國際專利技術VYCROSS™製造，全面地締造輪廓提昇、緊緻淡紋及改善膚質的效果9-11,15。一次療程即時見效，效果長達2年16！
永久溶脂17‡Belkyra®(有效成份)榮獲美國FDA及歐洲EMA雙認證18^,19，針對頑固的雙下巴脂肪，直接定點摧毀脂肪細胞17，永久減少脂肪數目。只需平均2-4次療程20，達致溶脂效果持久不反彈17,21。
雙效緊緻26*HArmonyCa™ 美神針透過嶄新科技高端結合透明質酸及 CaHA28 的雙效優點，即現拉提緊緻26*，並刺激膠原持續自生27†，以獨特的「C-shape拉提」帶來革新3重效果，全面還原初生緊緻！
BOTOX®保妥適®註冊藥物號碼: HK-41906. Juvéderm® (Hyaluronic Acid Gel with Lidocaine) 產品系列包括VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA®(HKMD-210451) 及VOLITE™ (HKMD-180040). CoolSculpting®註冊號碼: HKMD-190025. HArmonyCa™ (calcium hydroxyapatite, hyaluronic acid gel with lidocaine). ‡Minimal invasive treatment in adipolysis. ^Approved as Kybella™ in US18. *Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks.26 † Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 8 weeks.27 References: 1. Medical Insight, Inc 2022. Cosmetic Neurotoxin Market Study. January 2022. Based on worldwide neurotoxins 2021 (in sales value); 2. Allergan Aesthetics. Data on File. REF-108642. JUVÉDERM®, the world’s leading brand of hyaluronic acid facial fillers claim; 3. Medical Insight Inc. The Global Aesthetic Market Study: Version XVII. 2019; 4. De Boulle K, et al. Dermatol Surg. 2018;44(11):1437–48; 5. U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter 85-0226 & 85-0227, December 29, 1989; 6. Allergan Aesthetics. Data on File. REF-103043. BOTOX® 100 million vials. October 2022; 7. BOTOX® Prescribing Information. HK-41906. May 2013; 8. Trindade de Almeida AR et al. Dermatol Surg 2015; 41: S19-S28. 根據一份評估面部外觀的研究指出，89.7% BOTOX®用家認為他們看起來比實際年齡年輕; 9. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e; 10. De Maio M, et al. Plast Reconstr Surg. 2017 Oct;140(4):540e-550e; 11. De Maio M. et. al. Plast Reconstr Surg. 2017 Sep;140(3):393e-404e; 12. VOLUX™, VOLUMA®, VOLIFT®, VOLBELLA® 及 VOLITE ™ 均獲得歐盟 CE 認證. European Commission, Juvéderm hyaluronic acid based medical devices. EC certificate number: 3824296CE02; 3824296CE05; 3824296CE06; 3824296CE08; 3824296CE09, Mar 2020; 13. VOLUX™, VOLUMA®, VOLIFT® 及 VOLBELLA® (approval as VOLUX™ XC, VOLUMA® XC, VOLLURE® XC and VOLBELLA® XC in US) 均獲得美國 FDA 認證. U.S. Food and Drug Administration, Department of Health & Human Services. Juvéderm VOLUX XC approval letter P110033/S065, July 2022; Juvéderm VOLUMA XC approval letter P110033/S047, Jun 2020; Juvéderm VOLLURE XC approval letter P110033/S020, Mar 2017; Juvéderm VOLBELLA XC approval letter P110033/S053, May 2021; 14. Allergan Aesthetics. Data on File. REF-96563. FILLERS GLOBAL NUMBER OF SYRINGES. May 2022. 100 million Juvéderm® syringes manufactured worldwide from 2004 to April 2022; 15. Ogilvie P et al. J Cosmetic Dermatol. 2019; 00:1-6; 16. Callan P, et al. Clin Cosmet Investig Dermatol. 2013; 6:81-9; 17. Rzany B, et al. Br J Dermatol. 2014;170(2):445-453; 18. U.S. Food and Drug Administration, Department of Health & Human Services. Kyrbella™ deoxycholic acid injection, 10mg/ml approval letter NDA 206333, Apr 2015; 19. European Medicines Agency. List of nationally authorized medicinal products. EMA/753957/2017. November 2017; 20. Belkyra®️ Prescribing Information. March 2021; 21. Humphrey S, et al. J Am Acad Dermatol 2016;75(4):788-797; 222. FDA. K212707. ZELTIQ®️ CoolSculpting®️ system. October 2021; 23. Manstein D et al. Lasers Surg Med 2008; 40: 595-604, 24. Zelickson B, et al. Dermatol Surg 2009;35:1462–70, 25. Bernstein EF. J Cosmet Dermatol 2016;15:561–4; 26. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine INT-HAR-2150036. Lift capacity. July 2021; 27. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine INT-HAR-2150040. Collagen stimulation. July 2021. 28. HArmonyCa™ IFU. 20072591. M049 V02/P01. Revision December 2021.
HK-AGNA-230026 | 13/SEP/23
